For high-value pharmaceuticals — biologics, specialty medicines, sterile products — certification is not merely a market-entry licence but the plant’s brand asset: a factory recognised by the strictest regulators can sell to the whole world. Vietnam and Singapore place a plant at two very different systemic positions inside this global recognition order.
Two systemic positions: HSA inside PIC/S and Vietnam’s Drug Administration
Singapore regulates pharmaceuticals through its Health Sciences Authority (HSA), which is simultaneously a member of PIC/S — the international pharmaceutical inspection cooperation scheme — and of ICH, where technical registration requirements are harmonised. That membership carries concrete operational value: HSA’s GMP inspection outcomes are referenced by other member authorities under recognition and reliance mechanisms, letting a Singapore plant’s file travel between markets materially faster.
Vietnam manages drug registration and manufacturing through the Drug Administration of Vietnam under the Ministry of Health, with a GMP standards system issued through ministry circulars — currently including Circular 32/2026/TT-BYT (effective 1 October 2026, replacing Circular 12/2025/TT-BYT) within the Pharmacy Law framework as amended by Law 44/2024. Vietnam is not yet a PIC/S member, so domestic GMP assessment outcomes do not enjoy an equivalent reliance mechanism; a high-value export plant typically faces separate direct inspections by each destination market or by its customers.
Testing, registration and real capacity for high-value products
At the national testing tier, Vietnam fields the National Institute of Drug Quality Control and a provincial testing system serving marketing authorisation and post-market quality surveillance; Singapore fields HSA laboratories acting as a regional reference centre. For high-value medicines, the decisive arena is rarely national testing but a triad: the product registration dossier in each market (in the common CTD format), GMP inspection by the destination regulator (EMA in Europe, the FDA in the United States) and the plant’s own quality system run to EU-GMP or equivalent standard.
The practical difference between the two countries lies in support-ecosystem depth: Singapore offers ready regulatory-affairs talent, contract research organisations and multi-market registration experience accumulated through its regional pharma-hub role; Vietnam offers lower build and operating costs, a large home market raising its specialty-drug spend, and industrial policy prioritising pharmaceutical development — but the journey of a new plant to an EMA- or FDA-passed inspection remains a multi-year road in both countries, and in Vietnam it should be planned with a wider margin.
EU and US standards and compliance cost: what incentives cannot buy
For high-value medicines, EU and US standards apply in full wherever the plant sits: a drug sold into the EU needs marketing authorisation from the EMA or a member-state authority with an EU-standard GMP inspection passed; a drug sold into the US must clear the FDA with registration dossiers and facility inspection under cGMP. Host-country tax incentives soften none of these requirements — they only decide the economics after the certification problem has been solved.
Total compliance cost therefore comprises: building an international-standard quality system, registration and inspection fees in each market, and the high-specialisation people needed to hold continuous compliance. Recommendation by project profile: biologics and sterile high-value products aimed straight at the EU and the US in their first cycle — Singapore for systemic credibility and file speed; products targeting Vietnam and ASEAN first, with a staged upgrade path to international standards — Vietnam for the cost equation and the home market. All Singapore-regime details need local counsel confirmation in Singapore, and the Vietnamese side should be re-checked against the Ministry of Health’s latest instruments at project time.
Frequently Asked Questions
What mandatory certification applies to high-value pharma exports from each country (framework)?
Domestically: Vietnam through the Drug Administration of Vietnam with the Ministry of Health’s GMP system (the current frame includes Circular 32/2026/TT-BYT replacing Circular 12/2025/TT-BYT); Singapore through the HSA. Toward destination markets, the deciding certification is that market’s own marketing authorisation and GMP inspection (EMA for the EU, FDA for the US) — the production location cannot substitute for this layer.
Quality testing: which bodies, how long in each country?
Vietnam: the Drug Administration manages registration and licensing, with the National Institute of Drug Quality Control as the national testing body. Singapore: the HSA both regulates and, as a PIC/S and ICH member, has its inspection outcomes referenced more widely. For high-value products the full multi-market registration journey is measured in years in either country, with no single figure — plan it per market list.
Which EU/US standards apply when producing in each country?
They apply identically in full: the EU requires marketing authorisation and an EU-standard GMP inspection via the EMA or a member-state authority; the US requires FDA dossiers and facility inspection under cGMP. Host-country incentives reduce none of this; the only difference is how far domestic assessment outcomes are relied upon by destination regulators.
What does standards compliance cost in each country?
The largest block is building and maintaining an international-standard quality system, plus registration and inspection fees per destination market — equivalent in nature in both countries. Singapore costs more to operate but saves file time through its PIC/S position; Vietnam is cheaper to build and run but needs a wider time margin for the international recognition journey.
This article has been quality-reviewed by the FLAW AI Legal Council